

15. A composition comprising the VEGF variant of claim 1 and a carrier.

16. The composition of claim 15 wherein said carrier is a pharmaceutically acceptable carrier.

17. An assay to detect KDR receptor, comprising contacting a cell or tissue with the VEGF variant of claim 1 and detecting binding of said VEGF variant to KDR receptor(s) which may be present in or on said cell or tissue.

18. A method of stimulating vasculogenesis or angiogenesis,
10 comprising exposing mammalian cells expressing KDR receptor to an
effective amount of the VEGF variant of claim 1:

19. An article of manufacture, comprising a container holding the composition of claim 15 and a label on said container providing instructions for use of said composition *in vitro* or *in vivo*.

[Handwritten signature]